Vireo Q3 Revenue Jumps 177% to $253.7M; Issues First Q4/Q1 Guidance
VREOF is trading near its 52-week low of $6.4 (5.9% above the low).
Summary
Vireo reported Q3 2026 revenue of $253.7M (up 177%) and $42.7M of Adjusted EBITDA, then guided Q4 2026 to $250M-$265M of revenue and $45M-$48M of EBITDA. The growth is acquisition-driven and margins compressed, but the guidance implies roughly $1.1B annualized revenue.
Key Events · Earnings and Guidance · VREOF
-
Q3 Revenue Up 177% to $253.7M
GAAP revenue rose to $253.7M from $91.7M a year earlier, with cannabis revenue of $198.1M and non-cannabis revenue of $55.6M. Pro forma revenue including C21, PharmaCann Colorado and Cannabist Colorado was $277.0M.
-
Adjusted EBITDA $42.7M, Margin Compresses
Adjusted EBITDA grew 68.1% to $42.7M but margin fell to 16.8% from 27.7%, as non-cannabis gross margin of 15.0% and acquired operations diluted the mix. The quarter still posted a $24.0M net loss, or $0.49 per share.
-
First Guidance: Q4 and Q1 2027
Q4 2026 revenue guided to $250M-$265M with Adjusted EBITDA of $45M-$48M; Q1 2027 revenue guided to $280M-$300M with Adjusted EBITDA of $53M-$56M. Pending unclosed acquisitions could add $45M-$55M of Q4 revenue if completed.
-
Balance Sheet: $106.8M Cash, $186.2M Net Debt
Cash was $106.8M at September 30, 2026 against $293M of long-term debt, for net debt of $186.2M. The company also repurchased 216,200 subordinate voting shares for $2.5M under its August NCIB.
Analysis · VREOF · Life Sciences
Vireo's Q3 revenue of $253.7M is up 177% year-over-year, but the bigger news is the first formal guidance: Q4 2026 revenue of $250M-$265M with $45M-$48M of Adjusted EBITDA, and Q1 2027 revenue of $280M-$300M with $53M-$56M. That implies roughly $1.1B annualized revenue and about $200M of annualized EBITDA exiting the first quarter, which is the number that matters for a company carrying $293M of long-term debt. The catch is margin: Adjusted EBITDA margin fell to 16.8% from 27.7% a year ago as lower-margin non-cannabis revenue (15.0% gross margin) and acquired businesses diluted the mix, and the quarter still produced a $24.0M net loss. Cash of $106.8M against $186.2M of net debt leaves limited room, so the pending Planet 13 merger vote on December 10, 2026 is the next hard checkpoint.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VREOF was trading at $6.78 on OTC in the Life Sciences sector, with a market capitalization of approximately $349.8M. The 52-week trading range was $6.40 to $21.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.